Shaanxi YXchuang Biotechnology Co., Ltd
The compound on which the fluorescent label is dependent is called a fluorescent substance. A fluorescent substance refers to a compound having a chemical structure of a conjugated double bond system. When irradiated with ultraviolet light or blue-violet light, it can be excited to an excited state, and when it is restored from the excited state, it emits fluorescence. Fluorescent labeling technology refers to the use of a fluorescent substance to covalently bind or physically adsorb on a...
Polypeptides are complex macromolecules, so each sequence is unique in both physical and chemical properties. Some peptides are difficult to synthesize, while others are relatively easy to synthesize, but purification is difficult. The most common problem is that many peptides are insoluble in aqueous solution, so in purification, these hydrophobic peptides must be dissolved in a non-aqueous solvent, or a special buffer, and these solvents or buffers are likely to be unsuitable for use in...
English name: VE; Vitamin E; D-alpha-Tocopherol; (2R) -3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R, 8R) -4,8,12-trimethyltridecyl ] -2H-1-benzopyran-6-ol Other names: natural vitamin E; tocopherol; vitamin E; [2R- [2R * (4R *, 8R *)]]-3,4-dihydro-2,5,7,8-tetramethyl-2- (4,8,12-trimethyltridecyl) -6-chromanol; (+)-5,7,8-trimethyltocopherol CAS number: 59-02-9 C29H50O2 = 430.71 Content: ≥50.0% (HPLC) Loss on drying: ≤1.0% Heavy metals: ≤10ppm Arsenic: ≤1ppm Properties: White crystalline powder or...
Definition: Azithromycin is an antibiotic belonging to macrolide. It was discovered in 1980 and introduced in 1981. Also translated as a erythromycin, azithromycin. Azithromycin is a broad-spectrum antibiotic that has been modified on the structure of erythromycin and is suitable for respiratory tract infections, skin and soft tissue infections, and chlamydia-induced transmission diseases. The pharmacological azithromycin is a 15-membered aza compound obtained by a series of reactions such as...
“The prospects for the development of pharmaceutical intermediates in China are still promising.” This is the information that the reporter learned from the experts at the second seminar on pharmaceutical intermediates R&D progress and market prospects held in 2006. Recently, experts including Wang Pushan from the SFDA Information Center, Professor Liao Qingjiang from the China Pharmaceutical University, and Deputy Director Tao Jianhong from the SFDA Institute of Southern Medicine and...
On April 5, in the provincial-level eco-economic park in Mingxi County, the workers of Shunan Fine Chemicals Co., Ltd. are stepping up the installation of the second phase of high purity industrial oxygen and hydrogen equipment. The company is the only company producing hydrogen in northwestern Yunnan and is a supplier to Heisford Chemical Co., Ltd. In recent years, the Mingxi County Party Committee and County Government have taken the development of the fine fluorine chemical industry as an...
Recently, the Office of the Leading Group of the Special Action for Rectifying and Regulating the Pharmaceutical Market Order in Shangyu City, Zhejiang Province, organized a joint special inspection on 29 pharmaceutical intermediate production enterprises in the city. This special inspection adopts a combination of self-inspection and key spot checks. It mainly conducts comprehensive inspections on the implementation of key personnel of pharmaceutical intermediate production enterprises,...
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.